[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335923-105":59,"doc-detail-335923-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-mutation-load-better-predicts-the-prognosis-of-patients-treated-with-immune-checkpoint-inhibitors-in-upper-gastrointestinal-cancers-a-systematic-review-and-meta-analysis","Tumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers - A systematic review and meta-analysis","","Tumor mutational load (TML) is a proposed biomarker across solid tumors, but evidence for upper gastrointestinal (UGI) cancers is limited. This systematic review and meta-analysis evaluated whether TML predicts survival in UGI patients receiving immune checkpoint inhibitors. Searches in PubMed, Embase, Cochrane Library, and Web of Science (through February 13, 2023) identified 11 eligible studies and pooled hazard ratios for progression-free and overall survival using heterogeneity and bias assessments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-mutation-load-better-predicts-the-prognosis-of-patients-treated-with-immune-checkpoint-inhibitors-in-upper-gastrointestinal-cancers-a-systematic-review-and-meta-analysis/335923/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-mutation-load-better-predicts-the-prognosis-of-patients-treated-with-immune-checkpoint-inhibitors-in-upper-gastrointestinal-cancers-a-systematic-review-and-meta-analysis/335923.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the study address?","Question",{"text":112,"@type":113},"Whether tumor mutational load (TML) better predicts prognosis for upper gastrointestinal cancer patients treated with immune checkpoint inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was evidence collected for the meta-analysis?",{"text":117,"@type":113},"A comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science was performed up to February 13, 2023, and 11 studies met inclusion criteria.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main outcomes for high versus low TML groups?",{"text":121,"@type":113},"Compared with low TML, high TML in immunotherapy-treated UGI cancers showed significantly improved overall survival and progression-free survival, with pooled hazard ratios and 95% confidence intervals reported in the results.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335923,1790402988,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","DOI: 10.1002/cnr2.1959  \nO R IG INA L ARTI CLE  \nTumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers: A systematic review and meta-analysis  \nChenghao Ma 1\\#  | Qiong Teng 1\\# | Liang Shang 1,2 | Fengying Du 2 | Leping Li 1,2  \n1Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China 2Department of Gastrointestinal Surgery, Shandong Provincial Hospital  \nAffiliated to Shandong First Medical University, Jinan, China  \nCorrespondence  \nLeping Li, Department of Gastrointestinal Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, No. 324, Jingwu Road, Jinan, Shandong, China.  \nEmail: [lileping@medmail.com.cn](lileping@medmail.com.cn)  \nFunding information  \nKey Research and Development Program of Shandong Province, Grant/Award Number:  \n2021CXGC011104; Special Foundation for Taishan Scholars Program of Shandong Province, Grant/Award Number: ts20190978; National Natural Science Foundation of China, Grant/Award Number: 82203854  \nAbstract  \nBackground: Tumor mutational load (TML) has emerged as a potential biomarker for multiple solid tumors. However, data on its prognostic impact on upper gastrointestinal (UGI) cancer are limited. Therefore, the aim of this systematic review and metaanalysis was to assess the prognostic value of TML for the survival of patients with UGI cancer.  \nMethod: A comprehensive search of the PubMed, Embase, Cochrane Library, and Web of Science databases was conducted up to February 13, 2023 . Eleven studies met our inclusion criteria. Hazard ratios (HRs) for progression-free survival and overall survival and their 95% confidence intervals (CIs) were calculated. Subsequently, the combined HR and its 95% CI were calculated for UGI tract cancers in the high and low TML groups. I2 statistics and p-values were used to evaluate heterogeneity. Publication bias, sensitivity, and subgroup analyses were performed to determine sources of heterogeneity.  \nResults: In total, 932 patients with UGI tract cancer from 11 publications were included. The high TML group treated with immunotherapy showed significantly improved overall survival (HR = 0.68; 95% CI: 0.53, 0 .86; p = .001) and progression-free survival (HR = 0.74; 95% CI: 0 .58, 0 .95; p = .020) compared with the low TML group. Conclusion: Our study demonstrated that patients with UGI tumors and higher TML have a better prognosis with immunotherapy, suggesting that TML is a promising predictive biomarker for immunotherapy.  \nRegistration: The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO Registration No: CRD42023405596) .  \nKEYWOR DS  \nimmune checkpoint inhibitor, meta-analysis, prognosis, tumor mutation load, upper gastrointestinal cancers  \n\\# Chenghao Ma and Qiong Teng are the co-first authors.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.  \n1 | INTRODUCTION  \nUpper gastrointestinal (UGI) malignancies include gastric, gastroesophageal junction, and esophageal tumors. According to the World Health Organization's global cancer statistics, 1.09 million people are diagnosed with stomach cancer and 600 000 with esophageal cancer every year, making it the fourth most common cancer worldwide. The incidence of gastric cancer (GC) deaths was 770 000 and that of esophageal cancer deaths was 540 000, ranking second in total mortality among all tumors.1 Despite improvements in survival rates, the 5-year survival rate for advanced UGI tumors remains unsatisfactory, with cytotoxic chemotherapy being the primary treatment option.2,3 Immunotherapies have proven to be a promising option, changing the standard of care","cbCaienDvXCQRhPv","https://ap.wps.com/l/cbCaienDvXCQRhPv","pdf",1801489,"English","# Introduction\n## Upper gastrointestinal malignancies and rationale for biomarkers\n# Materials and Methods\n## Review registration and search strategy","[{\"question\":\"What clinical question does the study address?\",\"answer\":\"Whether tumor mutational load (TML) better predicts prognosis for upper gastrointestinal cancer patients treated with immune checkpoint inhibitors.\"},{\"question\":\"How was evidence collected for the meta-analysis?\",\"answer\":\"A comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science was performed up to February 13, 2023, and 11 studies met inclusion criteria.\"},{\"question\":\"What were the main outcomes for high versus low TML groups?\",\"answer\":\"Compared with low TML, high TML in immunotherapy-treated UGI cancers showed significantly improved overall survival and progression-free survival, with pooled hazard ratios and 95% confidence intervals reported in the results.\"}]","Tumor mutation load better predicts the prognosis of patients treated with immune checkpoint inhibitors in upper gastrointestinal cancers - A systematic review and meta-analysis | PDF",1790012846,25]